Is Nurtec (rimegepant) contraindicated in a patient with chronic kidney disease and type 1 diabetes mellitus?

Nurtec is NOT contraindicated in patients with CKD and type 1 diabetes

Nurtec (rimegepant) has no absolute contraindication related to chronic kidney disease or diabetes mellitus. The only contraindication is a history of hypersensitivity reaction to rimegepant or its components 1.

Renal Dosing Considerations

The FDA label and pharmacokinetic studies provide clear guidance on rimegepant use across different levels of kidney function:

For mild to severe renal impairment (eGFR ≥15 mL/min/1.73 m²):

• No dose adjustment is required 1
• Total rimegepant exposure increases by only ~40% in moderate renal impairment 1
• Severe renal impairment shows no clinically meaningful difference in total drug exposure compared to normal renal function 1

Important caveat: While total drug exposure remains acceptable, unbound (active) rimegepant concentrations increase 1.8-fold in moderate CKD and 2.6-fold in severe CKD 2. However, this has not translated into safety concerns in clinical practice.

For end-stage renal disease (eGFR <15 mL/min) or dialysis:

• Nurtec should be avoided as it has not been studied in this population 1, 2

Diabetes Considerations

Neither type 1 nor type 2 diabetes represents a contraindication or requires special dosing adjustments for rimegepant. The drug's mechanism as a CGRP receptor antagonist does not interfere with glucose metabolism 1.

A dedicated drug interaction study confirmed that rimegepant at steady state had no clinically significant impact on metformin pharmacokinetics or glucose utilization 1, which is particularly relevant for patients with diabetes who commonly use metformin.

Clinical Algorithm for Your Patient

For a patient with CKD and type 1 diabetes:

1. Determine eGFR - This is the critical decision point

   • eGFR ≥15 mL/min/1.73 m²: Nurtec can be used at standard dosing (75 mg)
   • eGFR <15 mL/min/1.73 m² or on dialysis: Avoid Nurtec

2. Check for hypersensitivity history - The only true contraindication

3. Assess hepatic function - While not mentioned in your question, severe hepatic impairment (Child-Pugh C) increases exposure 2-fold and requires caution 1

4. Consider drug interactions - Avoid strong CYP3A4 inhibitors (increase exposure 4-fold) 1

Key Safety Points

Rimegepant demonstrates a favorable cardiovascular safety profile without vasoconstrictive effects seen with triptans 3, which is particularly important in patients with CKD who have elevated cardiovascular risk. The drug can even be co-administered with triptans if needed 1, 3.

The presence of type 1 diabetes does not alter these recommendations, as the drug does not affect glucose homeostasis or interact with diabetes medications 1.